Company news
Aligos Therapeutics, Inc. (NASDAQ:ALGS) news
Aligos Therapeutics, Inc. news releases on 6ix. Latest, Oct 5, 2026: Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver…
Press releases & updates
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
October 5, 2026
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
October 4, 2026
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
September 2, 2026
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
August 12, 2026
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
July 13, 2026
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
July 6, 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
May 26, 2026
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
May 13, 2026
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
May 7, 2026
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
April 15, 2026
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
April 13, 2026
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
February 26, 2026
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
February 23, 2026
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 30, 2026
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
January 21, 2026
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
January 13, 2026
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics
January 8, 2026
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
December 11, 2025
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
November 10, 2025
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
November 6, 2025
Aligos Therapeutics to Present at Upcoming Investor Conferences
November 4, 2025
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
October 30, 2025
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
October 16, 2025
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
October 14, 2025
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
October 7, 2025
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
September 3, 2025
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
August 20, 2025
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
August 13, 2025
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
August 6, 2025
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
June 18, 2025
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2025
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
May 20, 2025
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
May 8, 2025
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
May 6, 2025
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
April 29, 2025
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
April 23, 2025
Aligos Therapeutics Presents Positive Data at APASL 2025
March 26, 2025
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
March 10, 2025
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
March 3, 2025
Aligos Therapeutics Announces $105 Million Private Placement Financing
February 11, 2025
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
November 18, 2024
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
November 5, 2024
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
October 21, 2024
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
October 14, 2024
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
September 30, 2024